Tuesday, January 25, 2022

Pfizer begins Omicron Vaccine trial

Pfizer has started a clinical trial to test a new vaccine that specifically targets the Omicron Variant of COVID-19.

The study will look at the safety, tolerability and immune response in adults aged 18-55 in the United States and South Africa.

Jagruti Dave reports from Washington.

In: "Pfizer BioNTech have..."
Out: "...them to Americans."
Dur: 48 sec

Clip: http://fsnradionews.com/feeds/0125Pfizer+Masks-jd.mp3